Alia Therapeutics, the first Italian CRISPR company, is developing new therapeutic approaches to treat incurable genetic diseases. Alia’s unique CRISPR-based genome editing tools allow unprecedented specificity in modifying the genome, coupled with safe and efficient delivery into target cells. Alia’s gene editing platform overcomes relevant limitations speeding up the development of genetic medicines.